# Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema

> **NCT05512962** · PHASE2 · COMPLETED · sponsor: **Oxular Limited** · enrollment: 25 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Triamcinolone Acetonide
- **DEVICE:** Semi-automated Suprachoroidal Microcatheter

## Key facts

- **NCT ID:** NCT05512962
- **Lead sponsor:** Oxular Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-31
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05512962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05512962, "Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05512962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*